• Home |
  • Reports |
  • Global Multi Cancer Early Detection Market: By Type (Liquid Biopsy, Gene Panel, LDT & Others); By En....

Global Multi Cancer Early Detection Market: By Type (Liquid Biopsy, Gene Panel, LDT & Others); By End-Use (Hospitals, Diagnostic Laboratories, Others); By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa) Global Industry Analysis, COVID-19 Impact, and Industry Forecast, 2018-2032.

  • We provide customized solutions to cater to your specific requirement services any region, product, or any specific market segment.
Market Overview/Outlook (2022 to 2032)

The global Multi Cancer Early Detection market is expected to grow between 2023 and 2032 due to factors like improved sensitivity and specificity, early intervention and treatment, advancements in liquid biopsy, and innovations in imaging technologies.

The Global Multi Cancer Early Detection Market was valued at USD 0.83 Billion in 2022 and is projected to reach USD 2.44 Billion by 2032, registering a CAGR of 14.15% for the forecast period 2023-2032.

Global Multi-Cancer Early Detection Market Drivers
  • Improved sensitivity and specificity: Cancer biomarker detection now has higher sensitivity and specificity thanks to developments in genomic and molecular technologies. This makes it possible to identify different cancer types more accurately, which helps with early detection.
  • Early intervention and treatment: The likelihood of a successful outcome is increased when cancer is detected early because it allows for prompt intervention and treatment. The market for multi-cancer early detection is largely driven by the emphasis on moving from late-stage diagnosis to early detection.
  • Increasing rate of cancer: The need for more thorough and effective screening techniques has been fueled by the rising incidence of cancer worldwide. The need for more comprehensive screening to cover a range of cancers is addressed by multi-cancer early detection technologies.
  • Advancements in Liquid Biopsy: Non-invasive methods for early cancer detection are made possible by liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA) and other biomarkers in blood. Interest in blood-based tests for multi-cancer screening is sparked by these developments.
  • Innovations in Imaging Technologies: By offering precise information about the presence and location of tumors, advanced imaging technologies like computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) help in the early detection of cancer.
Global Multi Cancer Early Detection Market – Merger and Acquisitions
  • Pfizer Completes Acquisition of Seagen (2023)
Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  • Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics (2023)
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received At least One Prior Systemic Treatment.
  • GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn (2022)
GlaxoSmithKline plc and Sierra Oncology, Inc announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion.
  • AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening hematological cancer pipeline (2022)
AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)I, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1. The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell hematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma. Building on the success of Calquence (acalabrut AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1.
Challenges Impacting the Global Multi-Cancer Early Detection Market
  • Testing Fee: High research and development costs may be associated with creating and implementing comprehensive multi-cancer screening methods. Furthermore, some populations may not be able to access certain cancer tests due to the high cost of testing for a wide variety of cancers.
  • Clinical Utility and Validation: Thorough research and data are needed to validate the clinical utility and efficacy of multi-cancer early detection techniques. Regulatory approval and healthcare professional acceptance of these tests depend on proving their accuracy and reliability in a variety of populations.
  • Challenges to Regulatory Approval: It is a difficult procedure to get regulatory approval for multi-cancer early detection tests. The time and expense required to introduce these tests into the market are increased by having to comply with the strict regulations set by regulatory bodies like the Food and Drug Administration (FDA) in the United States.
  • Legal and ethical issues: Careful consideration should be given to ethical issues, such as those about informed consent, privacy, and the possible psychological effects of learning about multiple cancer risks. To guarantee appropriate implementation, legal and regulatory frameworks need to take these issues into account. 
Attributes Details
Market Size in 2022 USD 0.83 Billion
Market Forecast in 2032 USD 2.44 Billion
Compound Annual Growth Rate (CAGR) 14.15 %
Unit Revenue (USD Million) and Volume (Kilo Tons)
Segmentation By Type, By End-Use & By Region
By Type
  • Liquid Biopsy
  • Gene Panel, LDT & Others
By End-User
  • Hopsitals
  • Diagnostic Laboratories
  • Others
By Region
  • North America: U.S and Canada
  • Europe: Germany, Italy, Russia, U.K, Spain, France, Rest of Europe
  • APAC: China, Australia, Japan, India, South Korea, South East Asia, Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Chile
  • The Middle East And Africa: South Africa, GCC, Rest of MEA
Base Year 2022
Historical Year 2018 - 2022
Forecast Year 2023 - 2032
Category-wise Analysis:

By Type:

  • Liquid Biopsy: A non-invasive substitute for conventional tissue biopsies is a liquid biopsy. A blood sample can be taken more easily, which increases patient acceptance and enables repeated testing over time. Genetic data from a variety of tumors located throughout the body can be obtained through liquid biopsies. CtDNA or CTCs can be present in the bloodstream before any clinical symptoms appear. Early intervention and treatment may be made easier by the ability of liquid biopsy to identify cancer at an earlier stage.
  • Gene Panel, LDT & Others: Gene panels entail the examination of several genes linked to various forms of cancer. The discovery of particular genetic biomarkers linked to different types of cancer makes a thorough early detection strategy possible. LDTs are tests that particular laboratories have created and approved. Laboratories can create tests based on particular genetic and molecular markers in the context of multi-cancer early detection, which helps to provide a more individualized approach.
By End-Use:

  • Hospitals: To provide complete healthcare services, including screening and diagnostics, hospitals are essential. A wider range of services can be provided by hospitals to their patients by integrating multi-cancer early detection methods. By addressing several possible cancer risks at once, multi-cancer early detection as part of standard healthcare services allows a more comprehensive approach to patient care. Due to their established infrastructure and accessibility, hospitals are a convenient place for patients to receive multi-cancer screening services.
  • Diagnostic Laboratories: Clinical validation studies are carried out by diagnostic laboratories to evaluate the precision, sensitivity, and specificity of multi-cancer early detection tests. To remain at the forefront of cancer research, many diagnostic laboratories work in conjunction with academic institutions and biotechnology companies. Clinical reporting and interpretation services are offered by diagnostic laboratories, giving medical professionals relevant and useful information.
Regional Analysis:

North America:
  • United States: The healthcare system in the United States is highly advanced and comprises a vast network of hospitals, clinics, and research institutes. Numerous esteemed research institutes, academic institutions, and medical facilities that are at the forefront of cancer research and innovation are located in the United States. Innovations in healthcare technologies, particularly those pertaining to multi-cancer early detection, are made possible by significant investments made in research and development (R&D) in the United States by both public and private entities.
  • Canada: The healthcare system in Canada is well-established and supported by the government. The sophisticated medical technologies, such as multi-cancer early detection methods, can be integrated and adopted on the basis of the nation's strong healthcare infrastructure. The nation's healthcare and research institutions work together to develop and validate new diagnostic technologies, which may include approaches for early detection of multiple cancers. New technology can be more easily incorporated into the Canadian healthcare system with the help of a well-defined regulatory framework.
Asia Pacific:
  • China: Progress in cancer diagnosis is facilitated by collaboration between international biotechnology companies, Chinese healthcare institutions, and research organizations. Collaborations and partnerships help advance the use of cutting-edge technologies. Certain cancers linked to infectious agents and lifestyle factors are highly prevalent in China. China's economy is growing, which has raised the country's spending on healthcare. This could lead to an increase in the need for cutting-edge medical services, such as early cancer detection, and a growing market for cutting-edge diagnostics.
  • India: India has a high incidence rate and a significant cancer burden. Numerous cancer types are caused by different lifestyle factors and a diverse population. For management and treatment to be effective, early detection is essential. In India, the public's knowledge of cancer and the value of early detection has grown. The need for early cancer detection services is driven by people who are proactive in seeking preventive healthcare and who are health-conscious. The Indian government's healthcare and cancer control initiatives could potentially aid in the advancement of early detection programs.
  • Southeast Asia: The expansion of the multi-cancer early detection market in Southeast Asia can be facilitated by private healthcare providers and businesses making investments in cancer diagnostics and early detection services. The adoption of multi-cancer early detection methods may be influenced by the prevalence of particular cancers in the area. For instance, comprehensive screening might be prioritized more if a particular type of cancer is more prevalent. The creation and uptake of novel screening technologies may be aided by the region's involvement in clinical research and trials linked to multi-cancer early detection.
  • Western Europe: In Western Europe, regulatory agencies like the European Medicines Agency (EMA) are essential in assessing and approving novel medical technologies. Validated multi-cancer early detection methods may be easier to introduce and adopt thanks to the regulatory framework in the region. In Western Europe, the general public's awareness of the value of cancer screening and early detection is frequently high. In Western Europe, patient advocacy groups are actively involved in promoting early detection techniques and increasing public awareness of different cancers.
  • Eastern Europe: The necessity for efficient screening and early detection methods may be driven by the cancer incidence in Eastern Europe. In areas where the incidence of cancer cases is higher, multi-cancer early detection technologies might become more significant. The implementation of multi-cancer early detection methods in Eastern European countries may be facilitated by advancements in healthcare infrastructure and increased accessibility to cutting-edge medical technologies. A favorable environment for the expansion of the multi-cancer early detection market may be created if governments in Eastern European nations undertake programs aimed at cancer prevention and early detection.
Latin America:
  • Brazil: The population's economic standing may affect the uptake of cutting-edge medical services. The acceptance and utilization of multi-cancer early detection tests may be influenced by their affordability and accessibility. It is essential to have a regulatory framework that supports advanced diagnostics approval and adoption. Brazil can promote market expansion if it has efficient and well-defined regulatory procedures for cancer detection technologies. Working together with foreign businesses and academic institutions can help make cutting-edge multi-cancer early detection technologies available in Brazil.
  • Mexico: Multi-cancer early detection solutions may be in high demand if the prevalence of different types of cancers is high in Mexico. Multi-cancer detection at the same time can be especially useful in areas with different cancer patterns. An important factor is Mexico's healthcare infrastructure, both in terms of quality and accessibility. The market may be driven by government programs and healthcare laws that emphasize early detection and cancer prevention.
Middle East and Africa:
  • Middle East: The Middle East has seen a rise in cancer cases in recent years, although the incidence of the disease varies by region. There may be a growing need for sophisticated and thorough screening techniques due to the rising incidence of cancer. Research organizations, technology companies, and healthcare facilities working together can improve multi-cancer screening methods' adoption and accessibility. Collaborations can result in the creation of successful screening initiatives.
  • Africa: Africa has a high cancer burden, with a variety of cancer types being common there. Because prompt diagnosis and intervention are essential, there is a high demand for efficient early detection techniques. Africa is seeing a rise in the incidence of cancer, in part because of aging populations, changing lifestyles, and population growth. The number of cancer cases rising highlights the significance of early detection programs. The lack of access to diagnostic services and other healthcare facilities is a problem in many African regions.
  • Australia and New Zealand: Tight legal requirements in both nations support a medical environment that puts patients' safety and effectiveness first. Regulatory compliance is a prerequisite for any new technology or diagnostic tool to be introduced to the market. Research and initiatives related to public health are funded in both Australia and New Zealand. Market expansion may be fueled by the incorporation of multi-cancer early detection techniques into public health campaigns or national cancer control plans. The adoption of cutting-edge medical technologies can be facilitated by participation in international clinical trials and cooperation with global healthcare organizations.

List of Prominent Players:
  • Grail, LLC (Illumina, Inc.)
  • Exact Sciences Corporation.
  • Foundation Medicine, Inc.
  • AnchorDx
  • Guardant Health, Inc.
  • Burning Rock Biotech Limited
  • Laboratory for Advanced Medicine, Inc.
  • Singlera Genomics Inc.
  • Others
Segmentation of Global Multi Cancer Early Detection Market:

By Type:
  • Liquid Biopsy
  • Gene Panel, LDT & Others
By End-Use:
  • Hopsitals
  • Diagnostic Laboratories
  • Others
By Region:
  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, Southeast Asia, Rest of APAC)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (GCC Countries, UAE, Rest of MEA)
No Methodology
No Available